Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, has announced the pricing of an underwritten public offering of 3,100,000 shares of its common stock at a public offering price of US$48.50 per share, for total gross proceeds of approximately US$150.4 million, before deducting underwriting discounts and commissions and offering expenses payable by Zentalis. All of the common stock is being offered by Zentalis. The offering is expected to close on July 1, 2021, subject to customary closing conditions. In addition, Zentalis has granted the underwriters a 30-day option to purchase up to an additional 465,000 shares of its common stock at the public offering price, less underwriting discounts and commissions.
Latham & Watkins LLP represents Zentalis Pharmaceuticals in the offering with a capital markets team led by New York partner Nathan Ajiashvili and San Diego partner Cheston Larson, with New York associates Salvatore Vanchieri, Matthew DeSilva, and Andrew Borruso.